Ligand Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	274.48	268.09	167.13	131.31	196.25	241.54
Revenue Growth (YoY)	51.24%	60.40%	27.28%	-33.09%	-18.75%	47.68%
Cost of Revenue	12.97	14.55	11.07	10.51	52.83	62.18
Gross Profit	261.5	253.54	156.06	120.8	143.42	179.37
Selling, General & Admin	94.48	92.45	78.65	52.79	70.06	46.79
Depreciation & Amortization Expenses	32.55	32.71	32.96	33.65	34.24	34.22
Research & Development	33.25	81.18	21.43	24.54	36.08	32.11
Other Operating Expenses	6.64	6.2	45.63	-	-	-37.6
Total Operating Expenses	166.92	212.54	178.67	110.98	140.38	75.52
Operating Income	94.59	41	-22.61	9.82	3.04	103.85
Interest Income	23.15	13.66	8.06	7.71	2.05	0.89
Interest Expense	-5.6	-4.72	-3.04	-0.66	-1.8	-19.62
Other Non-Operating Income (Expense)	90.3	117.96	25.12	51.72	32.97	-31.65
Total Non-Operating Income (Expense)	107.85	126.9	30.14	58.77	33.22	-50.38
Pretax Income	202.44	167.9	7.54	68.59	36.26	53.47
Provision for Income Taxes	-31.32	-34.51	-6.55	-9.84	-41.23	4.15
Net Income	153.56	124.45	-4.03	52.15	-33.36	57.14
Earnings From Discontinued Operations	-	-	-	-1.67	-28.14	-19.22
Net Income to Common	153.56	124.45	-4.03	52.15	-33.36	57.14
Shares Outstanding (Basic)	20	19	18	17	17	17
Shares Outstanding (Diluted)	20	20	18	18	17	17
Shares Change (YoY)	9.33%	10.96%	3.00%	5.27%	-2.19%	2.50%
EPS (Basic)	7.84	6.44	-0.22	3.02	-0.31	3.44
EPS (Diluted)	7.37	6.13	-0.22	2.94	-0.31	3.31
EPS Growth	-	-	-	-	-	748.72%
Shares Outstanding	20.03	19.77	19.11	17.56	16.95	16.77
Free Cash Flow	123.03	48.91	95.23	46.06	119.93	70.04
Free Cash Flow Growth	151.56%	-48.64%	106.76%	-61.60%	71.23%	39.72%
Free Cash Flow Per Share	6.03	2.41	5.21	2.59	7.11	4.06
Gross Margin	95.27%	94.57%	93.37%	91.99%	73.08%	74.26%
Operating Margin	34.46%	15.29%	-13.53%	7.48%	1.55%	42.99%
Profit Margin	85.17%	46.42%	-2.41%	40.98%	-2.66%	31.61%
FCF Margin	44.82%	18.24%	56.98%	35.07%	61.11%	29.00%
EBITDA	127.81	74.78	12.63	46.34	54.57	154.92
EBITDA Margin	46.56%	27.89%	7.56%	35.29%	27.81%	64.14%
EBIT	94.59	41	-22.61	9.82	3.04	103.85
EBIT Margin	34.46%	15.29%	-13.53%	7.48%	1.55%	42.99%
Effective Tax Rate	-15.47%	-20.55%	-86.92%	-14.35%	-113.71%	7.76%

Updated May 8, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q